ARQT FY2025 SEC EDGAR DEF 14A #107 of 168 in industry

Arcutis Biotherapeutics, Inc. CEO pay ratio

The CEO earned $7.2M in FY2025 against median worker pay of $262,613 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-21
Industry
Chemicals & Pharmaceuticals
Industry rank
#107/168

Data updated August 2026

Subscribe to Arcutis Biotherapeutics, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
28:1
Below Average (Scale: 0–1000:1)
CEO pay
$7.2M
Median worker
$262,613

Answer first

Arcutis Biotherapeutics, Inc.'s FY2025 CEO total of $7.2M ranks #754 of 1,423 complete filings; its 28:1 pay ratio ranks #1150. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $262,613. Industry placement uses the FY2025 SIC-28 peer cohort (# 107 of 168, 37th percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#754
$7.2M of 1,423 FY2025
Ratio rank
#1150
28:1 of 1,423
Industry pct
37th
below the industry median pay ratio

How Arcutis Biotherapeutics, Inc. ranks nationally

Arcutis Biotherapeutics, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$7,223,065 47th percentile higher than 47% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). This entry sits in this band. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Arcutis Biotherapeutics, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($7.2M) against pay ratio (28:1) for Arcutis Biotherapeutics, Inc. (marked) and its 3 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both03372161.56744323.010116484.613488646.127.3:131.2:135:138.9:142.7:1CEO total payPay ratio (CEO : median worker)Arcutis Biotherapeutics, Inc., CEO total pay: 7223065 · Pay ratio (CEO : median worker): 28:1Arcutis Biotherapeutics, Inc.Newmarket Corp, CEO total pay: 132938 · Pay ratio (CEO : median worker): 28:1Newmarket CorpStructure Therapeutics Inc., CEO total pay: 8520403 · Pay ratio (CEO : median worker): 29:1Structure Therapeutics Inc.Protagonist Therapeutics, Inc, CEO total pay: 12852660 · Pay ratio (CEO : median worker): 30:1Protagonist Therapeutics, Inc
Arcutis Biotherapeutics, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Arcutis Biotherapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Arcutis Biotherapeutics, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2022–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
28:1
FY2025
vs prior FY
+14:1
from FY2024 14:1
CEO $ YoY
+96%
$7.2M latest
Filings shown
3
FY2022–2025
Arcutis Biotherapeutics, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2022 $4.6M - $310,773 15:1 -
2024 $3.7M -19% $267,635 14:1 -1:1
2025 $7.2M +96% $262,613 28:1 +14:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1787306, FY2022–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
28:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$7.2M
Companies in Industry
168
vs. Industry Median
Below
#107 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Arcutis Biotherapeutics, Inc.: MODEST · HEAVY pay ratio

Arcutis Biotherapeutics, Inc.'s 28:1 ratio ranks #1150 of 1,423 FY2025 complete filings (lower third by ratio). the CEO earned 28× the median employee ($262,613) in FY2025.

Median employee $262,613 (ELITE-MED); MODEST · HEAVY stamps put about 28 median-wage years per CEO year.

CEO Total Pay

$7.2M

FY2025 Summary Compensation, near median

Pay Ratio

28:1

Below typical

Arcutis Biotherapeutics, Inc. in the lower-ratio third

Arcutis Biotherapeutics, Inc.'s 28:1 ratio ranks #1150 of 1,423 FY2025 complete filings (lower third by ratio). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Arcutis Biotherapeutics, Inc.'s $7.2M CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #754 and ratio rank #1150 split - treat 28:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$7.2M
Median Employee Pay
$262,613
Pay Ratio
28:1
Filing Date
2026-04-21

Company Info

Ticker
ARQT
CIK
1787306
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1787306, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Arcutis Biotherapeutics, Inc.'s 28:1 ratio ranks #1150 of 1,423 FY2025 complete filings (lower third by ratio).

Read with Arcutis Biotherapeutics, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

Progyny, Inc. · HEAVY

ABS(ceo_total_comp) peer at $7.2M (Δ $2K lighter vs Arcutis Biotherapeutics, Inc.); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Mimedx Group, Inc. · HEAVY

ABS(ceo_total_comp) peer at $7.2M (Δ $6K heavier vs Arcutis Biotherapeutics, Inc.); MODEST · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
EnerSys · HEAVY

ABS(ceo_total_comp) peer at $7.2M (Δ $7K heavier vs Arcutis Biotherapeutics, Inc.); MID · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Shake Shack Inc. · HEAVY

ABS(ceo_total_comp) peer at $7.2M (Δ $12K lighter vs Arcutis Biotherapeutics, Inc.); HIGH · LOW-MED vs this page's MODEST · HEAVY · ELITE-MED.
Cytokinetics Inc (SIC 28 pole)

Cytokinetics Inc stamps MODEST · UNFILED nearest in-SIC by ABS(pay_ratio) to Arcutis Biotherapeutics, Inc.'s MODEST filing.
National dual ranks · #754/#1150

Arcutis Biotherapeutics, Inc.'s FY2025 package sits #754 by CEO dollars and #1150 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

Arcutis Biotherapeutics, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Arcutis Biotherapeutics, Inc. (CIK 1787306), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.